DDInter1355 DDInter1008
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Azoles {u} (Pharmacologic Class) includes {v} (Compound) Ketoconazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) is included by Azoles (Pharmacologic Class) and Azoles (Pharmacologic Class) includes Ketoconazole (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ketoconazole (Compound)